PDF(Sci-hub)
Abstract：
BACKGROUND: The use of chemotherapy in advanced metastatic breast cancer remains a subject of controversy. The thought of MicKinnon et al (early 1950s) that the course of breast cancer was unaffected by chemotherapy has been refuted by results of treatment in the developed countries. The poor result of treatment in developing centres still compares with prechemotherapy era. Consequently, The McKinnon\'s thought may still lurk. We compared the survival of chemotherapy treated with chemotherapy untreated cancer of breast patients.
METHODS: Records of breast cancer patients who presented and died between January 2010 and May 2014 were reviewed. The primary outcome was overall survival. Records of patients that received chemotherapy with or without other tumor directed specific therapy were compared with records of patients who did not receive any tumor directed therapy.
RESULTS: Thirty-one patients received chemotherapy while 25 patients did not. All were females, more than 90% were of the patients had advanced or metastatic disease. Treatments were not biologically directed and treatment plans were largely compromised and suboptimal. The overall mean survival was 19.2 ±9.2 months, and the median duration was 17.5 months(range 6-44months). The overall survival was not statistically different between the two groups (p= 0.230, unequal variance assumed). The objective of using neoadjuvant chemotherapy for fungating lesions was not achieved.
CONCLUSIONS: In advanced and metastatic breast cancer, outcomes of patients who receive suboptimal regimen of cytotoxic chemotherapy do not differ from chemotherapy untreated patients.
METHODS: Records of breast cancer patients who presented and died between January 2010 and May 2014 were reviewed. The primary outcome was overall survival. Records of patients that received chemotherapy with or without other tumor directed specific therapy were compared with records of patients who did not receive any tumor directed therapy.
RESULTS: Thirty-one patients received chemotherapy while 25 patients did not. All were females, more than 90% were of the patients had advanced or metastatic disease. Treatments were not biologically directed and treatment plans were largely compromised and suboptimal. The overall mean survival was 19.2 ±9.2 months, and the median duration was 17.5 months(range 6-44months). The overall survival was not statistically different between the two groups (p= 0.230, unequal variance assumed). The objective of using neoadjuvant chemotherapy for fungating lesions was not achieved.
CONCLUSIONS: In advanced and metastatic breast cancer, outcomes of patients who receive suboptimal regimen of cytotoxic chemotherapy do not differ from chemotherapy untreated patients.
摘要：
背景：在晚期转移性乳腺癌中使用化疗仍是一个有争议的话题。MicKinnon等人（1950年代初）认为乳腺癌的病程不受化疗的影响，这已被发达国家的治疗结果所驳斥。与化疗前时代相比，发展中中心的治疗效果不佳。因此,麦金农的思想可能仍然潜伏。我们比较了乳腺癌患者化疗和化疗未治疗的生存率。
方法：回顾了2010年1月至2014年5月期间出现并死亡的乳腺癌患者的记录。主要结果是总生存率。将接受或不接受其他肿瘤定向特异性治疗的化疗患者的记录与未接受任何肿瘤定向治疗的患者的记录进行比较。
结果：31例患者接受化疗，25例未接受化疗。都是女性,超过90%的患者患有晚期或转移性疾病.治疗不是生物学指导的，治疗计划在很大程度上受到损害和次优。总平均生存期为19.2±9.2个月，中位病程为17.5个月(6-44个月).两组之间的总生存期没有统计学差异（p=0.230，假设不等方差）。未达到使用新辅助化疗治疗基础病变的目的。
结论：在晚期和转移性乳腺癌中，接受细胞毒性化疗方案次优的患者的结局与未接受化疗的患者没有差异.
方法：回顾了2010年1月至2014年5月期间出现并死亡的乳腺癌患者的记录。主要结果是总生存率。将接受或不接受其他肿瘤定向特异性治疗的化疗患者的记录与未接受任何肿瘤定向治疗的患者的记录进行比较。
结果：31例患者接受化疗，25例未接受化疗。都是女性,超过90%的患者患有晚期或转移性疾病.治疗不是生物学指导的，治疗计划在很大程度上受到损害和次优。总平均生存期为19.2±9.2个月，中位病程为17.5个月(6-44个月).两组之间的总生存期没有统计学差异（p=0.230，假设不等方差）。未达到使用新辅助化疗治疗基础病变的目的。
结论：在晚期和转移性乳腺癌中，接受细胞毒性化疗方案次优的患者的结局与未接受化疗的患者没有差异.
